Teleflex (NYSE:TFX) Reaches New 52-Week Low – Should You Sell?

Teleflex Incorporated (NYSE:TFX)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $195.25 and last traded at $195.25, with a volume of 191714 shares traded. The stock had previously closed at $198.03.

Analysts Set New Price Targets

TFX has been the topic of a number of analyst reports. Truist Financial reiterated a “hold” rating and issued a $227.00 price target (down from $255.00) on shares of Teleflex in a research report on Monday. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research report on Friday, November 1st. Royal Bank of Canada decreased their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Mizuho dropped their price objective on Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Finally, Stephens boosted their target price on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $259.25.

Teleflex Trading Up 0.5 %

The firm has a market capitalization of $9.24 billion, a price-to-earnings ratio of 39.37, a P/E/G ratio of 2.07 and a beta of 1.18. The business has a 50 day moving average of $236.38 and a two-hundred day moving average of $223.78. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.38 by $0.11. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. During the same quarter in the prior year, the company posted $3.64 earnings per share. Teleflex’s revenue was up 2.4% compared to the same quarter last year. Equities analysts predict that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be given a $0.34 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.68%. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Insider Buying and Selling at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the transaction, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.43% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teleflex

A number of large investors have recently modified their holdings of the stock. Oregon Public Employees Retirement Fund boosted its position in Teleflex by 1.2% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock valued at $846,000 after acquiring an additional 46 shares in the last quarter. Cromwell Holdings LLC grew its stake in Teleflex by 59.0% in the third quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 49 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Teleflex by 1.9% in the second quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock worth $584,000 after purchasing an additional 53 shares in the last quarter. Apollon Wealth Management LLC lifted its position in Teleflex by 3.7% during the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock valued at $377,000 after buying an additional 55 shares during the period. Finally, Empirical Finance LLC boosted its holdings in shares of Teleflex by 3.9% during the 1st quarter. Empirical Finance LLC now owns 1,564 shares of the medical technology company’s stock valued at $354,000 after buying an additional 58 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.